Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | S100A4 | P26447 | 1/20 | 0.45 |
| ▸ | EDNRB | P24530 | 1/20 | 0.42 |
| ▸ | EDNRA | P25101 | 1/20 | 0.42 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30737888 | 1.00 | AR (0.46) | ARADORA3HSD11B1AKR1C3S100A4 | |
| SCHEMBL19302757 | 1.00 | AR (0.46) | ARADORA3HSD11B1AKR1C3S100A4 | |
| SCHEMBL11869980 | 1.00 | AR (0.46) | ARADORA3HSD11B1AKR1C3S100A4 | |
| (-)-4-Hydroxy-Alpha-Tetralone SCHEMBL3694170 | 0.81 | POLL (0.50) | ARADORA3HSD11B1AKR1C3S100A4 | |
| (-)-4-Hydroxy-Alpha-Tetralone SCHEMBL14592023 | 0.81 | POLL (0.50) | ARADORA3HSD11B1AKR1C3S100A4 | |
| (-)-4-Hydroxy-Alpha-Tetralone SCHEMBL19420220 | 0.81 | POLL (0.50) | ARADORA3HSD11B1AKR1C3S100A4 | |
| SCHEMBL8673469 | 0.80 | S100A4 (0.59) | ARADORA3HSD11B1AKR1C3S100A4 | |
| SCHEMBL12405330 | 0.79 | S100A4 (0.47) | ARADORA3HSD11B1AKR1C3S100A4 | |
| SCHEMBL19774841 | 0.78 | MEN1 (0.39) | ARADORA3HSD11B1AKR1C3S100A4 | |
| SCHEMBL14166580 | 0.78 | CYP2A6 (0.46) | ARADORA3HSD11B1AKR1C3S100A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190926-A1 | P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | CODEXIS, INC. | 2024-06-13 | — | — | US | claimed |
| CN-113072435-B | Preparation method of 3-hydroxy-1-indanone derivative containing alkenyl fluorine | 浙江工业大学 | 2022-04-29 | — | — | CN | claimed |
| CN-113072435-A | Preparation method of 3-hydroxy-1-indanone derivative containing alkenyl fluorine | 浙江工业大学 | 2021-07-06 | — | — | CN | claimed |
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | THE BROAD INSTITUTE, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250376656-A1 | MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250215464-A1 | ENGINEERED ENZYME FOR PREPARING A HYDROXYLATED INDANONE INTERMEDIATE USEFUL IN THE SYNTHESIS OF BELZUTIFAN | MERCK SHARP & DOHME LLC (US) | 2025-07-03 | — | — | US | disclosed |
| CN-119546622-A | Engineering enzymes for preparing hydroxylated indanone intermediates useful for synthesis of bezotevans | 默沙东有限责任公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20240190926-A1 | P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | CODEXIS, INC. | 2024-06-13 | — | — | US | disclosed |
| WO-2024112781-A1 | P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | CODEXIS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024042217-A1 | METHODS OF MODIFYING METHYLCYTOSINE OR DERIVATIVE THEREOF USING A NUCLEOPHILIC MOLECULE, AND METHODS OF USING THE SAME TO DETECT THE METHYLCYTOSINE OR DERIVATIVE THEREOF IN A POLYNUCLEOTIDE | ILLUMINA, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024010783-A1 | ENGINEERED ENZYME FOR PREPARING A HYDROXYLATED INDANONE INTERMEDIATE USEFUL IN THE SYNTHESIS OF BELZUTIFAN | MERCK SHARP & DOHME LLC (US) | 2024-01-11 | — | — | WO | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20120231972-A1 | Probe Compound for Detecting and Isolating Enzymes and Means and Methods Using the Same | INSTITUTE OF CATALYSIS (CSIC) (ES) | 2012-09-13 | — | — | US | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-4078934-A | Photosensitive, image-forming composition containing a leuco 2,3-disubstituted-1-indanone and a photooxidant | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-03-14 | — | — | US | disclosed |
| US-3992450-A | PHOTOSENSITIVE COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | AR 254/4885ADORA3 203/4885HSD11B1 256/4885 |
| US-20120231972-A1 | Probe Compound for Detecting and Isolating Enzymes and Means and Methods Using the Same | SI, GUSB, MPI | AR 3427/4885ADORA3 2034/4885HSD11B1 508/4885 |
| US-20240190926-A1 | P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | CYP3A43, CYP4F3, CYP1A2 | AR 636/4885ADORA3 865/4885HSD11B1 84/4885 |
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | STUB1, SAMM50, CD14 | AR 4066/4885ADORA3 3764/4885HSD11B1 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.